FLT3-ITD impedes retinoic acid, but not arsenic, responses in murine acute promyelocytic leukemias.
Ontology highlight
ABSTRACT: Acute promyelocytic leukemia (APL) is often associated with activating FLT3 signaling mutations. These are highly related to hyperleukocytosis, a major adverse risk factor with chemotherapy-based regimens. APL is a model for oncogene-targeted therapies: all-trans retinoic acid (ATRA) and arsenic both target and degrade its ProMyelocytic Leukemia/Retinoic Acid Receptor α (PML/RARA) driver. The combined ATRA/arsenic regimen now cures virtually all patients with standard-risk APL. Although FLT3-internal tandem duplication (ITD) was an adverse risk factor for historical ATRA/chemotherapy regimens, the molecular bases for this effect remain unknown. Using mouse APL models, we unexpectedly demonstrate that FLT3-ITD severely blunts ATRA response. Remarkably, although the tran
SUBMITTER: Esnault C
PROVIDER: S-EPMC6440296 | biostudies-literature | 2019 Mar
REPOSITORIES: biostudies-literature
ACCESS DATA